Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps "

被引:0
|
作者
Wang, Xu [1 ,2 ,3 ]
Wang, Pu [1 ,2 ,3 ]
Liao, Ying [1 ,2 ,3 ]
Zhao, Xuan [1 ,2 ,3 ]
Hou, Rui [4 ]
Li, Sijin [1 ,2 ,3 ]
Guan, Zhangchun [1 ,2 ,3 ]
Jin, Yuhang [1 ,2 ,3 ]
Ma, Wen [1 ,2 ,3 ]
Liu, Dan [1 ,2 ,3 ]
Zheng, Junnian [2 ,3 ]
Shi, Ming [1 ,2 ,3 ]
机构
[1] Xuzhou Med Univ, Canc Inst, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Ctr Clin Oncol, Affiliated Hosp, 99 Huaihai Rd, Xuzhou 221002, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
[4] Xuzhou Med Univ, Coll Pharm, Xuzhou, Jiangsu, Peoples R China
关键词
Cancer; Drug resistance; Evolutionary Trap; CAR -T therapy; PDPN; LAPATINIB RESISTANCE; CELLS; CANCER; CARCINOMA;
D O I
10.1016/j.phrs.2024.107221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Based on the concept of "Evolutionary Traps", targeting survival essential genes obtained during tumor drug resistance can effectively eliminate resistant cells. While, it still faces limitations. In this study, lapatinib-resistant cells were used to test the concept of "Evolutionary Traps" and no suitable target stand out because of the identified genes without accessible drug. However, a membrane protein PDPN , which is low or non -expressed in normal tissues, is identified as highly expressed in lapatinib-resistant tumor cells. PDPN CAR -T cells were developed and showed high cytotoxicity against lapatinib-resistant tumor cells in vitro and in vivo , suggesting that CAR -T may be a feasible route for overcoming drug resistance of tumor based on "Evolutionary Trap". To test whether this concept is cell line or drug dependent, we analyzed 21 drug -resistant tumor cell expression profiles reveal that JAG1, GPC3, and L1CAM, which are suitable targets for CAR -T treatment, are significantly upregulated in various drug -resistant tumor cells. Our findings shed light on the feasibility of utilizing CAR -T therapy to treat drug -resistant tumors and broaden the concept of the "Evolutionary Trap".
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Modulating tumor physical microenvironment for fueling CAR-T cell therapy
    Luo, Zhong
    Yao, Xuemei
    Li, Menghuan
    Fang, De
    Fei, Yang
    Cheng, Zhuo
    Xu, Yingying
    Zhu, Bo
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 185
  • [42] Pseudoprogression in CAR-T cell therapy for solid tumor: Case report
    Zhao, Xuan
    Liu, Yanfen
    Qin, Guohui
    Ge, Yan
    Li, Qinglong
    Chen, Xinfeng
    Tian, Ximei
    Yu, Yong
    Ren, Jiangtao
    Zhang, Yi
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [43] Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
    Nan, Feifei
    Fu, Xiaorui
    Chen, Xinfeng
    Li, Ling
    Li, Xin
    Wu, Jingjing
    Feng, Xiaoyan
    Wu, Xiaolong
    Yan, Jiaqin
    Zhang, Mingzhi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
    Chunrun Qu
    Hao Zhang
    Hui Cao
    Lanhua Tang
    Haoyang Mo
    Fangkun Liu
    Liyang Zhang
    Zhenjie Yi
    Lifu Long
    Luzhe Yan
    Zeyu Wang
    Nan Zhang
    Peng Luo
    Jian Zhang
    Zaoqu Liu
    Weijie Ye
    Zhixiong Liu
    Quan Cheng
    Molecular Cancer, 21
  • [45] A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs.
    Granger, David
    Harrasser, Micaela
    Evans, Rachel
    Muczynski, Vincent
    Chester, Kerry
    Nathwani, Amit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
    Fernandez, Ariel
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (01) : 5 - 8
  • [47] Next-generation CAR T cells designed to overcome tumor resistance
    Mackall, Crystal L.
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
    Kaczanowska, Sabina
    Murty, Tara
    Alimadadi, Ahmad
    Contreras, Cristina F.
    Duault, Caroline
    Subrahmanyam, Priyanka B.
    Reynolds, Warren
    Gutierrez, Norma A.
    Baskar, Reema
    Wu, Catherine J.
    Michor, Franziska
    Altreuter, Jennifer
    Liu, Yang
    Jhaveri, Aashna
    Duong, Vandon
    Anbunathan, Hima
    Ong, Claire
    Zhang, Hua
    Moravec, Radim
    Yu, Joyce
    Biswas, Roshni
    Nostrand, Stephen Van
    Lindsay, James
    Pichavant, Mina
    Sotillo, Elena
    Bernstein, Donna
    Carbonell, Amanda
    Derdak, Joanne
    Klicka-Skeels, Jacquelyn
    Segal, Julia E.
    Dombi, Eva
    Harmon, Stephanie A.
    Turkbey, Baris
    Sahaf, Bita
    Bendall, Sean
    Maecker, Holden
    Highfill, Steven L.
    Stroncek, David
    Glod, John
    Merchant, Melinda
    Hedrick, Catherine C.
    Mackall, Crystal L.
    Ramakrishna, Sneha
    Kaplan, Rosandra N.
    CANCER CELL, 2024, 42 (01) : 35 - 51.e8
  • [49] CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
    Pagotto, Sara
    Simeone, Pasquale
    Brocco, Davide
    Catitti, Giulia
    De Bellis, Domenico
    Vespa, Simone
    Di Pietro, Natalia
    Marinelli, Lisa
    Di Stefano, Antonio
    Veschi, Serena
    De Lellis, Laura
    Verginelli, Fabio
    Kaitsas, Francesco
    Iezzi, Manuela
    Pandolfi, Assunta
    Visone, Rosa
    Tinari, Nicola
    Caruana, Ignazio
    Di Ianni, Mauro
    Cama, Alessandro
    Lanuti, Paola
    Florio, Rosalba
    CANCERS, 2023, 15 (04)
  • [50] Identification of cancer-specific cell surface targets for CAR-T cell therapy
    Hosen, Naoki
    INFLAMMATION AND REGENERATION, 2024, 44 (01)